Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Accumetrics’ VerifyNow P2Y12 Test has received CE mark to identify patients with high residual platelet reactivity on antiplatelet therapy and at greater risk for future cardiovascular events.
Subscribe to our email newsletter
The VerifyNow System helps physicians find an individual’s platelet response to multiple antiplatelet agents.
It provides information to help physicians make informed treatment decisions, as it addresses every major antiplatelet drug including aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel (Plavix)) and GP IIb/IIIa inhibitors.
Accumetrics president and CEO Timothy Still said also considering the recent inclusion of platelet reactivity testing in both the ACCF/AHA UA/NSTEMI Guidelines and the STS/SCA Blood Conservation Guidelines, the VerifyNow System is making a significant impact on how physicians are treating their cardiovascular patients.